Clinical Trial Update: Expanded Access to REGN4461 for Patients With Diseases Associated With Deficient Leptin Signaling

View source ↗

Summary

Regeneron announced expanded access to REGN4461 for patients with diseases tied to deficient leptin signaling, including lipodystrophy and monogenic obesity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Generalized Lipodystrophy
• Lipodystrophy
• Monogenic Obesity

Drugs mentioned

• REGN4461

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Lipodystrophy, Generalized Lipodystrophy (GLD) | Status: AVAILABLE